The new approach: psychosocial functioning as a necessary outcome criterion for therapeutic success in schizophrenia

被引:103
作者
Juckel, Georg [1 ]
Morosini, Pier Luigi [2 ]
机构
[1] Ruhr Univ Bochum, Dept Psychiat, LWL Univ Hosp, D-44791 Bochum, Germany
[2] Italian Natl Inst Hlth, Natl Ctr Epidemiol & Hlth Surveillance & Promot, Rome, Italy
关键词
International Classification of Functioning; Disability and Health; Mini-ICF-P; psychosocial performance scale; social functioning;
D O I
10.1097/YCO.0b013e328314e144
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Purpose of review Although in the past most attention was paid to psychopathology, these days outcome parameters such as cognitive and occupational performance, emotional stability, quality of life and psychosocial functioning are being recognized as important determinants of treatment success. Instead of only reducing the symptoms, therapy with antipsychotics must attain higher goals such as remission and recovery today. Recent findings The Psychosocial Performance Scale offers a validated, reliable and operational tool to assess the psychosocial functioning of patients during the course of treatment as well as in the acute state. The Mini-ICF-P might be a similar instrument for measuring psychosocial functioning. Summary In the future, medication and non-medication treatment strategies will also be judged by the ability to improve the psychosocial functioning of patients with schizophrenia, as measured by the Personal and Social Performance scale and the Mini-ICF-P.
引用
收藏
页码:630 / 639
页数:10
相关论文
共 43 条
  • [1] Neurocognitive functioning in schizophrenia: A trial of risperidone versus haloperidol
    Addington, J
    Addington, D
    [J]. CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE, 1997, 42 (09): : 983 - 983
  • [2] Remission in schizophrenia: Proposed criteria and rationale for consensus
    Andreasen, NC
    Carpenter, WT
    Kane, JM
    Lasser, RA
    Marder, SR
    Weinberger, DR
    [J]. AMERICAN JOURNAL OF PSYCHIATRY, 2005, 162 (03) : 441 - 449
  • [3] Angermeyer MC, 1999, PSYCHIAT PRAX, V26, P56
  • [4] Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder
    Bilder, RM
    Goldman, RS
    Volavka, J
    Czobor, P
    Hoptman, M
    Sheitman, B
    Lindenmayer, JP
    Citrome, L
    McEvoy, J
    Kunz, M
    Chakos, M
    Cooper, TB
    Horowitz, TL
    Lieberman, JA
    [J]. AMERICAN JOURNAL OF PSYCHIATRY, 2002, 159 (06) : 1018 - 1028
  • [5] Predicting schizophrenia patients' real-world behavior with specific neuropsychological and functional capacity measures
    Bowie, Christopher R.
    Leung, Winnie W.
    Reichenberg, Abraham
    McClure, Margaret M.
    Patterson, Thomas L.
    Heaton, Robert K.
    Harvey, Philip D.
    [J]. BIOLOGICAL PSYCHIATRY, 2008, 63 (05) : 505 - 511
  • [6] Bowie CR, 2006, MT SINAI J MED, V73, P993
  • [7] Determinants of real-world functional performance in schizophrenia subjects: Correlations with cognition, functional capacity, and symptoms
    Bowie, CR
    Reichenberg, A
    Patterson, TL
    Heaton, RK
    Harvey, PD
    [J]. AMERICAN JOURNAL OF PSYCHIATRY, 2006, 163 (03) : 418 - 425
  • [8] Social functioning as an outcome measure in schizophrenia studies
    Burns, T.
    Patrick, D.
    [J]. ACTA PSYCHIATRICA SCANDINAVICA, 2007, 116 (06) : 403 - 418
  • [9] Evolution of outcome measures in schizophrenia
    Burns, Tom
    [J]. BRITISH JOURNAL OF PSYCHIATRY, 2007, 191 : S1 - S6
  • [10] Davidson M, 1999, AM J PSYCHIAT, V156, P1328